ArticleBioinformation2025
Genetic and epigenetic alterations in oral potentially malignant disorders: A cross-sectional clinical study.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oxidative stress and antioxidant markers in oral leukoplakia: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Whole-Exome Sequencing Identifies Recurrent Germline-Associated and Somatic Variants in Oral Squamous Cell Carcinoma from Southwest India.Biomedicines · 2026Article
- Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence and spectrum of genetic and epigenetic alterations in oral potentially malignant disorders (OPMDs) is of interest. Hence, a total of 132 patients with clinically and histopathologically diagnosed OPMDs were evaluated for key molecular changes, including TP53 mutations, promoter methylation of tumor suppressor genes and global DNA hypomethylation. Salivary and tissue samples were analyzed using PCR, methylation-specific PCR (MSP) and immunohistochemistry. TP53 mutations and p16INK4a promoter hypermethylation were significantly associated with severe dysplasia and higher malignant transformation risk. Thus, integrating molecular profiling into OPMD evaluation could improve risk stratification and early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.